MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer

Molecular and Cellular Proteomics

Volumn 4, Issue 9, 2005, Pages 1341-1349

  Dekker, Lennard J ^a   Boogerd, Willem ^b   Stockhammer, Guenther ^c   Dalebout, Johannes C ^a   Siccama, Ivar ^d   Zheng, Pingpin ^a   Bonfrer, Johannes M ^b   Verschuuren, Jan J ^e   Jenster, Guido ^a   Verbeek, Marcel M ^f   Luider, Theo M ^a   Sillevis Smitt, Peter A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d Chordiant Software Inc   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE;

ADULT; AGED; ALGORITHM; ARTICLE; BIOINFORMATICS; BREAST CANCER; CEREBROSPINAL FLUID CYTOLOGY; COMPUTER PROGRAM; CONTROLLED STUDY; DETERIORATION; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MENINGEAL METASTASIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SENSITIVITY AND SENSIBILITY;

ADULT; BREAST NEOPLASMS; CHEMICAL FRACTIONATION; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MASS SPECTROMETRY; MENINGEAL NEOPLASMS; MIDDLE AGED; PEPTIDE MAPPING; PEPTIDES; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRYPSIN;

EID: 26844511377     PISSN: 15359476     EISSN: None     Source Type: Journal    
DOI: 10.1074/mcp.M500081-MCP200     Document Type: Article

References (31)

1. DeAngelis, L. M. (1998) Current diagnosis and treatment of leptomeningeal metastasis. J. Neurooncol. 38, 245-252
2. Zheng, P. P., Luider, T. M., Pieters, R., Avezaat, C. J., van den Bent, M. J., Sillevis Smitt, P. A., and Kros, J. M. (2003) Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J. Neuropathol. Exp. Neurol. 62, 855-862
3. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., and Liotta, L. A. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577
4. Fishman, R. A. (1992). Cerebrospinal Fluid in Diseases of the Nervous System, W. B. Saunders Company, Philadelphia
5. Pusch, W., Flocco, M. T., Leung, S.-M., and Thiele, H. (2003) Mass spectrometry-based clinical proteomics. Pharmacogenomics 4, 463-476
6. Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O., Corthals, G., Burkhard, P., Hochstrasser, D. F., and Sanchez, J. C. (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3, 1486-1494
7. Diamandis, E. P. (2003) Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem. 49, 1272-1275
8. Diamandis, E. P., and van der Merwe, D. E. (2005) Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin. Cancer Res. 11, 963-965
9. Diamandis, E. P. (2004) Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl. Cancer Inst. 96, 353-356
10. Diamandis, E. P. (2004) Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics 3, 367-378
11. Koomen, J. M., Zhao, H., Li, D., Abbruzzese, J., Baggerly, K., and Kobayashi, R. (2004) Diagnostic protein discovery using proteolytic peptide targeting and identification. Rapid Commun. Mass Spectrom. 18, 2537-2548
12. Ramstrom, M., Palmblad, M., Markides, K. E., Hakansson, P., and Bergquist, J. (2003) Protein identification in cerebrospinal fluid using packed capillary liquid chromatography Fourier transform ion cyclotron resonance mass spectrometry. Proteomics 3, 184-190
13. Dekker, L. J., Dalebout, J. C., Siccama, I., Jenster, G., Sillevis Smitt, P. A., and Luider, T. M. (2005) A new method to analyze matrix-assisted laser desorption/ionization time-of-flight peptide profiling mass spectra. Rapid Commun. Mass Spectrom. 19, 865-870
14. Koza, J. R. (1992). Genetic Programming, MIT Press, Cambridge, MA
15. Efron, B., and Tibshirani, R. (1986) Bootstrap methods for standard errors, confidence intervals, and other measures of accuracy. Stat. Sci. 1, 54-77
16. Efron, B., and Tibshirani, R. (1993). An Introduction to the Bootstrap, Chapman and Hall, New York
17. Straathof, C. S., de Bruin, H. G., Dippel, D. W., and Vecht, C. J. (1999) The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J. Neurol. 246, 810-814
18. Freilich, R. J., Krol, G., and DeAngelis, L. M. (1995) Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann. Neurol. 38, 51-57
19. Soltys, S. G., Shi, G., Tibshirani, R., Giaccia, A. J., Koong, A. C., and Le, Q. (2003) The use of plasma SELDI-TOF MS proteomic patterns for detection of head and neck squamous cell cancers (HNSCC). Int. J. Radiat. Oncol. Biol. Phys. 57, S202
20. Baggerly, K. A., Morris, J. S., and Coombes, K. R. (2004) Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20, 777-785
21. Check, E. (2004) Proteomics and cancer: running before we can walk? Nature 429, 496-497
22. White, C. N., Chan, D. W., and Zhang, Z. (2004) Bioinformatics strategies for proteomic profiling. Clin. Biochem. 37, 636-641
23. Diamandis, E. P. (2004) How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer. Clin. Chem. 50, 793-795
24. Diamandis, E. P. (2004) Proteomic patterns to identify ovarian cancer: 3 years on. Expert Rev. Mol. Diagn. 4, 575-577
25. Diamandis, E. P. (2004). Identification of serum amyloid a protein as a potentially useful biomarker for nasopharyngeal carcinoma. Clin. Cancer Res. 10, 5293; author reply 5293-4
26. Rogers, M. A., Clarke, P., Noble, J., Munro, N. P., Paul, A., Selby, P. J., and Banks, R. E. (2003) Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res. 63, 6971-6983
27. Qu, Y., Adam, B.-L., Yasui, Y., and Ward, M. D. (2002) Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostrate cancer from noncancer patients. Clin. Chem. 48, 1835-1843
28. Villanueva, J., Philip, J., Entenberg, D., Chaparro, C. A., Tanwar, M. K., Holland, E. C., and Tempst, P. (2004) Serum Peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 76, 1560-1570
29. Heike, Y., Hosokawa, M., Osumi, S., Fujii, D., Aogi, K., Takigawa, N., Ida, M., Tajiri, H., Eguchi, K., Shiwa, M., Wakatabe, R., Arikuni, H., Takaue, Y., and Takashima, S. (2005) Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system. Anticancer Res. 25, 1197-1203
30. Malik, G., Ward, M. D., Gupta, S. K., Trosset, M. W., Grizzle, W. E., Adam, B. L., Diaz, J. I., and Semmes, O. J. (2005) Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin. Cancer Res. 11, 1073-1085
31. Allard, L., Lescuyer, P., Burgess, J., Leung, K. Y., Ward, M., Walter, N., Burkhard, P. R., Corthals, G., Hochstrasser, D. F., and Sanchez, J. C. (2004) ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 4, 2242-2251